美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

LB Pharmaceuticals Inc

24.01

+0.31001.31%

盤後：24.080.0700+0.29%16:04 EST

成交量：12.28萬

成交額：293.70萬

市值：6.87億

市盈率：-32.30

高：24.25

開：23.63

低：23.46

收：23.70

52周最高：24.95

52周最低：13.36

股本：2,860.57萬

流通股本：1,900.00萬

量比：0.69

換手率：0.65%

股息：- -

股息率：- -

每股收益(TTM):-0.7433

每股收益(LYR):-250.6146

淨資產收益率：--

總資產收益率：--

市淨率：2.21

市盈率(LYR):-0.10

資料載入中...

總覽公司新聞資訊公告

LB製藥宣佈完成1億美元私募配售

Lb Pharmaceuticals Inc盤中異動臨近午盤股價大跌5.21%

LB Pharmaceuticals啓動雙相抑鬱症II期Illuminate-1試驗拓展LB-102研發管線

Lb Pharmaceuticals Inc盤中異動早盤急速下挫5.22%報20.27美元

LB製藥強化領導團隊任命企業事務及人力與文化部門高管

LB製藥強化領導團隊，企業事務及人力與文化部門迎來關鍵任命

Aktis Oncology申請美國IPO，生物技術公司上市反彈

新聞稿：LB Pharmaceuticals根據納斯達克上市規則5635(c)(4)向新員工授予誘因獎勵

新聞稿：LB Pharmaceuticals任命Kaya Pai Panandiker為首席商業官

Lb Pharmaceuticals Inc盤中異動大幅上漲5.48%報15.41美元

LB Pharmaceuticals Inc - 預計現有現金、現金等價物和可交易證券能夠支持計劃運作至2028年第二季度

LB Pharmaceuticals任命William Kane和Rekha Hemrajani加強董事會

異動解讀 | LB製藥（LBRX）美股上市首日盤中大漲90%，新藥研發前景看好

美股異動 | LB Pharmaceuticals(LBRX.US)登陸美股市場開盤升逾20%

LB Pharmaceuticals IPO定價15美元/股，今晚登陸納斯達克

生物科技IPO「解凍」！LB Pharmaceuticals(LBRX.US)IPO定價14-16美元/股，擬籌資2.5億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LBRX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals Inc","latestPrice":24.01,"timestamp":1771880400000,"preClose":23.7,"halted":0,"volume":122770,"hourTrading":{"tag":"盘后","latestPrice":24.08,"preClose":24.01,"latestTime":"16:04 EST","volume":3410,"amount":81878.37955,"timestamp":1771880678327,"change":0.07,"changeRate":0.002915,"amplitude":0},"delay":0,"changeRate":0.013080168776371404,"floatShares":19000000,"shares":28605700,"eps":-0.743267,"marketStatus":"盤後交易","change":0.31,"latestTime":"02-23 16:35:41 EST","open":23.63,"high":24.25,"low":23.46,"amount":2937001.97203,"amplitude":0.033333,"askPrice":38.06,"askSize":200,"bidPrice":22.96,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-0.743267,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1771894800000},"marketStatusCode":4,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":23.7,"postHourTrading":{"tag":"盘后","latestPrice":24.08,"preClose":24.01,"latestTime":"16:04 EST","volume":3410,"amount":81878.37955,"timestamp":1771880678327,"change":0.07,"changeRate":0.002915,"amplitude":0},"volumeRatio":0.686145},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":19000000,"roa":"--","roe":"--","lyrEps":-250.614601,"volumeRatio":0.686145,"shares":28605700,"dividePrice":0,"high":24.25,"amplitude":0.033333,"preClose":23.7,"low":23.46,"week52Low":13.36,"pbRate":"2.21","week52High":24.9499,"institutionHeld":0,"latestPrice":24.01,"committee":0.333333,"eps":-0.743267,"divideRate":0,"volume":122770,"delay":0,"ttmEps":-0.743267,"open":23.63,"prevYearClose":22.26,"prevWeekClose":23.7,"prevMonthClose":21.45,"prevQuarterClose":22.26,"fiveDayClose":23.34,"twentyDayClose":23.91,"sixtyDayClose":16.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1768021200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-02-20","current":-31.886254,"percent":0.018018,"low":-32.760749,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"high":-0.410019,"avg":-21.453793,"sd":8.088277,"marketCap":612238268},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268}],"updateTime":1771855554164},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1124088225","title":"LB製藥宣佈完成1億美元私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1124088225","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124088225?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 21:11","pubTimestamp":1770297074,"startTime":"0","endTime":"0","summary":"纽约，2026年2月5日——专注于开发精神分裂症、双相抑郁等神经精神疾病创新疗法的后期生物制药公司LB Pharmaceuticals Inc今日宣布，已与特定机构投资者签署证券购买协议，通过私募方式发行3,306,571股普通股及可认购最多1,417,107股普通股的预融资权证。普通股发行价为每股21.17美元，预融资权证发行价为每股21.1699美元。在扣除交易费用前，本次私募预计可为公司筹集约1亿美元总收益，交易预计于2026年2月6日左右完成，最终需满足惯例交割条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","BK4213","LBRX","LB","BK4007"],"gpt_icon":0},{"id":"2609823303","title":"Lb Pharmaceuticals Inc盤中異動 臨近午盤股價大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609823303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609823303?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 00:38","pubTimestamp":1770223120,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日00时38分，Lb Pharmaceuticals Inc股票出现波动，股价大幅下挫5.21%。截至发稿，该股报20.73美元/股，成交量1.5171万股，换手率0.06%，振幅8.18%。Lb Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.37%。Lb Pharmaceuticals Inc公司简介：LB Pharmaceuticals Inc 是一家临床阶段生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205003840953fd96e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205003840953fd96e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"1167670995","title":"LB Pharmaceuticals啓動雙相抑鬱症II期Illuminate-1試驗 拓展LB-102研發管線","url":"https://stock-news.laohu8.com/highlight/detail?id=1167670995","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167670995?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 21:02","pubTimestamp":1769432543,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals近日正式启动针对双相抑郁症的II期临床试验Illuminate-1，标志着其核心候选药物LB-102的研发版图实现重要拓展。该试验旨在评估LB-102在双相抑郁患者中的疗效与安全性，为这一难治性精神疾病提供潜在创新疗法。\nIlluminate-1试验的推进不仅深化了LB-102的临床开发路径，更彰显了公司对精神神经疾病治疗领域的战略聚焦。通过阶段性临床试验数据的积累，LB Pharmaceuticals有望进一步验证该药物的治疗潜力，为后续研发决策提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"gpt_icon":0},{"id":"2604391875","title":"Lb Pharmaceuticals Inc盤中異動 早盤急速下挫5.22%報20.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604391875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604391875?lang=zh_tw&edition=fundamental","pubTime":"2026-01-17 00:17","pubTimestamp":1768580279,"startTime":"0","endTime":"0","summary":"北京时间2026年01月17日00时17分，Lb Pharmaceuticals Inc股票出现异动，股价大幅跳水5.22%。截至发稿，该股报20.27美元/股，成交量4.6651万股，换手率0.18%，振幅6.20%。Lb Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.12%。Lb Pharmaceuticals Inc公司简介：LB Pharmaceuticals Inc 是一家临床阶段生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117001759953d1c42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117001759953d1c42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"1144226221","title":"LB製藥強化領導團隊 任命企業事務及人力與文化部門高管","url":"https://stock-news.laohu8.com/highlight/detail?id=1144226221","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144226221?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:05","pubTimestamp":1767701159,"startTime":"0","endTime":"0","summary":"纽约，2026年1月6日——临床阶段生物制药公司LB制药今日宣布，任命Ellen Rose为高级副总裁，主管企业事务；同时任命Lindsay Beaupre为高级副总裁，负责人力与文化部门。该公司专注于开发治疗精神分裂症、双相抑郁症及其他神经精神疾病的新型疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","LBRX","BK4120","BK4007","LB","BK4213","TISI"],"gpt_icon":0},{"id":"1104130764","title":"LB製藥強化領導團隊，企業事務及人力與文化部門迎來關鍵任命","url":"https://stock-news.laohu8.com/highlight/detail?id=1104130764","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104130764?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700876,"startTime":"0","endTime":"0","summary":"LB制药近日宣布对其领导团队进行重要人事调整，在企业事务及人力与文化部门任命了关键高管，以进一步巩固公司的管理架构。\n此次任命旨在加强公司内部治理与人才发展战略，通过引入资深管理人才提升组织效能。新任命的高管将负责推动企业文化建设、人才发展体系优化以及内外部沟通策略的完善。\n公司表示，这一系列人事变动将有助于提升企业运营效率，为未来的业务拓展奠定坚实基础。通过强化领导团队，LB制药展现出对组织发展与人才战略的高度重视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"gpt_icon":0},{"id":"2592118027","title":"Aktis Oncology申請美國IPO，生物技術公司上市反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=2592118027","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592118027?lang=zh_tw&edition=fundamental","pubTime":"2025-12-20 06:45","pubTimestamp":1766184351,"startTime":"0","endTime":"0","summary":"Aktis Oncology申请美国IPO，生物技术公司上市反弹路透12月19日 - Aktis Oncology公司周五在美国提交了首次公开募股申请，生物技术行业的股市上市在经历了放缓后出现反弹。Aktis Oncology 公司由生物技术投资者托德-福里于 2020 年 8 月共同创立，目前正在开发治疗多种实体瘤的药物。Aktis Oncology 的主要候选药物 AKY-1189 正在进行早期研究，以治疗某些实体瘤，包括一种晚期膀胱癌、乳腺癌和结直肠癌。Aktis Oncology 公司的前身是 HotKnot Therapeutics 公司，将在纳斯达克上市，股票代码为 \"AKTS\"。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL4T3XP1JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","LU1791807156.HKD","LU1880398554.USD","LU0130103400.USD","EVMN","LU2129689431.USD","LU0256863811.USD","BK4534","LU0477156797.USD","IE0001KFT4U8.USD","LU2129689514.USD","LU1074936037.SGD","LU1668664300.SGD","LU0320765489.SGD","BAC","LU1363072403.SGD","IE0034235188.USD","IE00BLSP4452.SGD","LU0648001328.SGD","LU1804176565.USD","LU1201861165.SGD","LU0052756011.USD","LU0256863902.USD","IE00BKVL7J92.USD","LU0321505439.SGD","IE00BZ1G4Q59.USD","BK4585","LU0980610538.SGD","MPLT","IE00BBT3K403.USD","LU0128525689.USD","LU0648000940.SGD","LU1069347547.HKD","MNSH","LU0130517989.USD","LU1883839398.USD","LU1201861249.SGD","LU0203347892.USD","BK4553","LU1035773651.USD","LU0234572021.USD","LU0306806265.USD","LU1894683348.USD","OWL","IE00B7SZLL34.SGD","LU1162221912.USD","LU0130102774.USD","LU0310800965.SGD","LU0306807586.USD","LBRX"],"gpt_icon":0},{"id":"1159324610","title":"新聞稿：LB Pharmaceuticals根據納斯達克上市規則5635(c)(4)向新員工授予誘因獎勵","url":"https://stock-news.laohu8.com/highlight/detail?id=1159324610","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159324610?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 06:09","pubTimestamp":1765404561,"startTime":"0","endTime":"0","summary":"纽约，2025年12月10日—— LB Pharmaceuticals Inc今天宣布，公司已向新的首席商业官Kaya Pai Panandiker授予一项股权奖励，该奖励超出但需遵循LB Pharmaceuticals Inc 2025年股权激励计划的条款与条件。该股权奖励于2025年12月10日授予，依据纳斯达克上市规则5635中提供的“诱因授予”例外，旨在作为Pai Panandiker女士进入LB Pharmaceuticals工作的诱因。Pai Panandiker女士获得了以21.36美元的行使价格购买195,000股LB Pharmaceuticals普通股的期权，行使价格为授予日LB Pharmaceuticals普通股的收盘价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX","NQmain","BK4213","BK4233","LB"],"gpt_icon":0},{"id":"1171700583","title":"新聞稿：LB Pharmaceuticals任命Kaya Pai Panandiker為首席商業官","url":"https://stock-news.laohu8.com/highlight/detail?id=1171700583","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171700583?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 21:05","pubTimestamp":1762952747,"startTime":"0","endTime":"0","summary":"纽约，2025年11月12日—— LB Pharmaceuticals Inc，一家专注于开发针对精神分裂症、双相抑郁症及其他神经精神疾病新疗法的临床阶段生物制药公司，今天宣布任命Kaya Pai Panandiker为首席商业官。“我们非常高兴欢迎Kaya加入LB Pharmaceuticals， ”首席执行官Heather Turner表示。“此刻加入LB Pharmaceuticals是个令人兴奋的时机，因为我们正准备推进一种针对精神分裂症和双相抑郁症的差异化疗法，有潜力惠及更广泛的神经精神疾病患者， ”Ms. Pai Panandiker表示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","R","BK4213","BK4232","BK4022","BK4233","LB","BK4007"],"gpt_icon":0},{"id":"2582192310","title":"Lb Pharmaceuticals Inc盤中異動 大幅上漲5.48%報15.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582192310","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582192310?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 01:01","pubTimestamp":1762880496,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日01时01分，Lb Pharmaceuticals Inc股票出现异动，股价大幅拉升5.48%。截至发稿，该股报15.41美元/股，成交量1.6191万股，换手率0.06%，振幅5.70%。Lb Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为1.30%。其相关个股中，Engene Holdings Inc C/Wts 31/10/2028  Cl A、Engene Holdings Inc.、天演药业涨幅较大，Quoin Pharmaceuticals Ltd、Salarius Pharmaceuticals, Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为2759.59%、389.11%、370.59%，振幅较大的相关个股有Engene Holdings Inc C/Wts 31/10/2028  Cl A、Quoin Pharmaceuticals Ltd、Engene Holdings Inc.，振幅分别为75.38%、58.48%、54.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112010136a6f271fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112010136a6f271fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"1172318551","title":"LB Pharmaceuticals Inc - 預計現有現金、現金等價物和可交易證券能夠支持計劃運作至2028年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1172318551","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172318551?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 21:14","pubTimestamp":1762434867,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc - 预计现有现金、现金等价物和可交易证券能够支持计划运作至2028年第二季度","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"1143506269","title":"LB Pharmaceuticals任命William Kane和Rekha Hemrajani加強董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1143506269","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143506269?lang=zh_tw&edition=fundamental","pubTime":"2025-09-25 20:31","pubTimestamp":1758803516,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals宣布通过任命William Kane和Rekha Hemrajani两位新成员来加强其董事会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"1124155235","title":"異動解讀 | LB製藥（LBRX）美股上市首日盤中大漲90%，新藥研發前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1124155235","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124155235?lang=zh_tw&edition=fundamental","pubTime":"2025-09-12 00:14","pubTimestamp":1757607260,"startTime":"0","endTime":"0","summary":"生物科技公司LB制药今日在美国股市上市交易，盘中股价大涨90%，引发市场高度关注。该公司专注于开发治疗神经精神疾病的药物，其首次公开发行价格为15美元。LB制药的主打产品是一种名为LB-102的口服小分子药物，主要用于治疗急性精神分裂症。公司计划于2026年第一季度开始LB-102的三期临床试验。这一进展表明LB制药在神经精神疾病治疗领域具有巨大潜力，投资者对公司的发展前景持乐观态度。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LBRX"],"gpt_icon":0},{"id":"2566531990","title":"美股異動 | LB Pharmaceuticals(LBRX.US)登陸美股市場 開盤升逾20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566531990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566531990?lang=zh_tw&edition=fundamental","pubTime":"2025-09-12 00:03","pubTimestamp":1757606604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159837","LB","BK4233","LBRX","BK4134","BK4213","III"],"gpt_icon":0},{"id":"2566958325","title":"LB Pharmaceuticals IPO定價15美元/股，今晚登陸納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2566958325","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566958325?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 11:53","pubTimestamp":1757562824,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，致力于开发神经精神疾病药物的生物科技公司LB Pharmaceuticals周三表示，其在美国首次公开募股中筹集了2.85亿美元，这是2月以来规模最大的生物科技IPO。此次IPO对LB Pharmaceuticals的估值为3.015亿美元。在由高增长、科技型公司主导的IPO市场中，LB Pharmaceuticals的上市意味着生物科技IPO走出寒冬。LB Pharmaceuticals明确意识到了这一挑战。LB Pharmaceuticals预计将于2026年第一季度开始III期临床试验。LB Pharmaceuticals将于周四在纳斯达克上市，股票代码为“LBRX”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LB Pharmaceuticals IPO定价15美元/股，今晚登陆纳斯达克","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LBRX"],"gpt_icon":0},{"id":"2566661519","title":"生物科技IPO「解凍」！LB Pharmaceuticals(LBRX.US)IPO定價14-16美元/股，擬籌資2.5億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566661519","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566661519?lang=zh_tw&edition=fundamental","pubTime":"2025-09-09 15:04","pubTimestamp":1757401462,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，致力于开发神经精神疾病药物的生物科技公司LB Pharmaceuticals周一公布了IPO定价条款。按照拟议发行价区间的中点计算，LB Pharmaceuticals市值将达到3.015亿美元。LB Pharmaceuticals预计将打破10多年来最长的生物科技IPO寒冬，成为自2025年2月Aardvark Therapeutics上市后首个规模较大的生物科技IPO。LB Pharmaceuticals预计将于2026年第一季度开始III期临床试验。LB Pharmaceuticals成立于2015年，计划在纳斯达克上市，股票代码为“LBRX”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LBRX","LB","BK4213","BK4233","159837"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}